CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expression

Chimeric antigen receptor (CAR) T-cells targeting CD19 demonstrate remarkable efficacy in treating B-lineage acute lymphoblastic leukemia (BL-ALL), yet up to 39% of treated patients relapse with CD19(−) disease. We report that CD19(−) escape is associated with downregulation, but preservation, of ta...

Descripción completa

Detalles Bibliográficos
Autores principales: Fousek, Kristen, Watanabe, Junji, Joseph, Sujith K., George, Ann, An, Xingyue, Byrd, Tiara T., Morris, Jessica S., Luong, Annie, Martínez-Paniagua, Melisa A., Sanber, Khaled, Navai, Shoba A., Gad, Ahmed Z., Salsman, Vita S., Mathew, Pretty R., Kim, Hye Na, Wagner, Dimitrios L., Brunetti, Lorenzo, Jang, Albert, Baker, Matthew L., Varadarajan, Navin, Hegde, Meenakshi, Kim, Yong-Mi, Heisterkamp, Nora, Abdel-Azim, Hisham, Ahmed, Nabil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7519582/
https://www.ncbi.nlm.nih.gov/pubmed/32205861
http://dx.doi.org/10.1038/s41375-020-0792-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7519582/
https://www.ncbi.nlm.nih.gov/pubmed/32205861
http://dx.doi.org/10.1038/s41375-020-0792-2

Ejemplares similares